Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
scPharmaceuticals Inc (SCPH)
NASDAQ:SCPH
Holding SCPH?
Track your performance easily
SCPH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.24 - $6.71
Previous Close$4.23
Volume381.83K
Average Volume (3M)276.83K
Market Cap
$211.62M
Enterprise Value$214.49M
Total Cash (Recent Filing)$38.50M
Total Debt (Recent Filing)$41.36M
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Nov 13, 2024EPS Estimate
-$0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.56
Shares Outstanding50,028,787
10 Day Avg. Volume191,616
30 Day Avg. Volume276,830
Standard Deviation0.17
R-Squared0.00181
Alpha0.00849
Financial Highlights & Ratios
Price to Book (P/B)21.83
Price to Sales (P/S)8.80
Price to Cash Flow (P/CF)-2.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.92
Enterprise Value/Gross Profit21.93
Enterprise Value/Ebitda-4.15
Forecast
1Y Price Target
$20.75Price Target Upside427.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
scPharmaceuticals News
PremiumCompany Announcements
scPharmaceuticals Reports Strong Growth in Q3 2024
PremiumCompany Announcements
scPharmaceuticals Secures Funding, Advances FUROSCIX CommercializationBulls Say, Bears Say
Bulls Say
Product DemandIncreased demand, with 15% growth in doses filled, should improve with the recent changes to their fulfillment hub.
Regulatory ApprovalThe FDA approved scPharma's sNDA for Furoscix in Class IV heart failure, notably expanding its label to all NYHA functional classes of HF patients.
Sales PerformanceScpharma reported $8.1MM in Furoscix Q2 sales, reflecting impressive year-over-year growth of 392%.
Bears Say
Financial PerformanceAt the end of 2Q24, scPharma’s cash position was $38.5M, not inclusive of recent financings, with OpEx slightly up Q/Q at $22.5M.
Operational IssuesThe Change Healthcare cyberattacks had a ~10% impact on prescriptions filled in the quarter, translating to lost sales of $600K-$700K.
Product LaunchSCPH stock has been under pressure as investors wait for signs of a more tangible launch inflection for Furoscix in decompensated heart failure (HF).
---
Ownership Overview
19.33% Insiders
6.05% Mutual Funds
6.46% Other Institutional Investors
62.60% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SCPH FAQ
What was scPharmaceuticals Inc’s price range in the past 12 months?
scPharmaceuticals Inc lowest stock price was $3.24 and its highest was $6.71 in the past 12 months.
What is scPharmaceuticals Inc’s market cap?
Currently, no data Available
When is scPharmaceuticals Inc’s upcoming earnings report date?
scPharmaceuticals Inc’s upcoming earnings report date is Nov 13, 2024 which is 10 days ago.
How were scPharmaceuticals Inc’s earnings last quarter?
scPharmaceuticals Inc released its earnings results on Aug 14, 2024. The company reported -$0.44 earnings per share for the quarter, missing the consensus estimate of -$0.418 by -$0.022.
Is scPharmaceuticals Inc overvalued?
According to Wall Street analysts scPharmaceuticals Inc’s price is currently Undervalued.
Does scPharmaceuticals Inc pay dividends?
scPharmaceuticals Inc does not currently pay dividends.
What is scPharmaceuticals Inc’s EPS estimate?
scPharmaceuticals Inc’s EPS estimate is -$0.3.
How many shares outstanding does scPharmaceuticals Inc have?
scPharmaceuticals Inc has 50,028,786 shares outstanding.
What happened to scPharmaceuticals Inc’s price movement after its last earnings report?
scPharmaceuticals Inc reported an EPS of -$0.44 in its last earnings report, missing expectations of -$0.418. Following the earnings report the stock price went up 5.637%.
Which hedge fund is a major shareholder of scPharmaceuticals Inc?
Among the largest hedge funds holding scPharmaceuticals Inc’s share is Perceptive Advisors LLC. It holds scPharmaceuticals Inc’s shares valued at N/A.
---
scPharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.75 (427.99% Upside)
$20.75 (427.99% Upside)
Blogger Sentiment
Bullish
SCPH Sentiment 100%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Decreased
By 2.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.3%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.84%
12-Months-Change
Fundamentals
Return on Equity
-166.89%
Trailing 12-Months
Asset Growth
-42.67%
Trailing 12-Months
Company Description
scPharmaceuticals Inc
scPharmaceuticals, Inc.engages in the development of transformative pharmaceutical products for subcutaneous delivery. Its products include furosemide, used as parenteral diuretic in treating heart failure and ceftriaxone, used as parenteral antibiotic outside the hospital setting. The company was founded by Pieter Muntendam and Bertram Pitt in February 2013 and is headquartered in Burlington, MA.
---
SCPH Earnings Call
Q2 2024
0:00 / 0:00
---
SCPH Stock 12 Month Forecast
Average Price Target
$20.75
▲(427.99% Upside)
Technical Analysis
Best Analysts Covering SCPH
1 Year
1 Year Success Rate
7/18 ratings generated profit
1 Year Average Return
+0.09%
reiterated a buy rating 3 months ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 38.89% of your transactions generating a profit, with an average return of +0.09% per trade.
---